BCL2 and acute lymphoblastic leukemia: The identification of BCL2 dependence in TCF3::HLF ALL as a druggable target demonstrates how the integration of drug response profiling and molecular genetic analysis might inform the development of novel treatment regimens in individuals with intractable therapeutic requirements.